ABVC BioPharma, Inc. - Common Stock (ABVC)

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SILICON VALLEY, CA - August 14, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, central nervous system (CNS) disorders, and oncology/hematology, today announced its financial results for the second quarter ended June 30, 2025. The Company continues to advance strategic initiatives aimed at stabilizing operations, strengthening its balance sheet, and building long-term shareholder value across its global platform.

ABVC’s 28,000 sq ft Silicon Valley Manufacturing Facility Stands Ready as Global Supply Chains Realign and Trust-based Localization Becomes Key

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Total licensing revenue crosses $1.046 million; strategic collaboration with OncoX evolves toward expanded product development and global oncology footprint

With Total Milestone Payments Reaching $946,000, ABVC Deepens Its Ophthalmology Focus Through a High-potential Partnership With ForSeeCon

SILICON VALLEY, CA - August 6, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, is pleased to share that it has received continued investment support from international investors. These investors, after an independent evaluation of the Company’s business and operations, made a private investment into the Company’s equity; demonstrating belief in the Company’s current and future plans.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SILICON VALLEY, CA - August 1, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today shared a strategic update on its ongoing collaboration with OncoX BioPharma, Inc., a rising oncology player that has licensed four IND-stage drug assets from ABVC. The two companies have taken another step forward, as OncoX continues to unlock funding to support product advancement under its bold, innovation-driven roadmap.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Licensing-first Strategy Continues to Deliver Non-dilutive Revenue; ABVC Positions Itself as a Leader in CNS-focused Botanical Therapeutics

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SILICON VALLEY, CA - June 26, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, proudly announces that a podcast with Biotech Orbit ( https://youtu.be/TYrNEA0mG-8?si=xnCCjK1ZrRIw8OK7 ), featured the Company’s Chief Executive Officer, Dr. Uttam Patil, among their list of the most influential Indian-origin CEOs leading major global organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SILICON VALLEY, CA - June 24, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it has converted its initial $100,000 convertible note into 10,000 shares of common stock of AiBtl BioPharma Inc. at a conversion price of $10 per share .

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SILICON VALLEY, CA - June 6, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that its affiliate, OncoX BioPharma Inc., has entered into a definitive agreement to acquire full ownership of the Lycopenoid Lycogen® platform, including patented manufacturing technology and commercialization rights, from Asia-Pacific Biotech Developing Inc. (APBDI). The transaction, structured as an equity-based acquisition, reflects a total value of approximately USD $4.06 million. [1]

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Silicon Valley, CA - ( NewMediaWire ) - June 03, 2025 - – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that its Board of Directors approved a plan to distribute, one share of stock of AiBtl BioPharma Inc. ("AIBTL"), a corporation organized and existing and under the laws of the State of Delaware, as a dividend reward to its shareholders for each share of ABVC common stock owned by the shareholder (the "AIBTL Shares"). Based on the Company’s current holdings, the Company expects to distribute approximately 15M AIBTL Shares. The distrubtion shall take place after the AIBTL Shares are included in an effective registration statement under the Securities Act of 1933, of which there is no guarantee.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SILICON VALLEY, CA - May 14, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that it has received official notice from the Nasdaq Listing Qualifications Department confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.